PROGNOSTIC FACTORS FOR RESECTABLE COMMON BILE DUCT CANCER
https://doi.org/10.17709/2409-2231-2019-6-2-7
Abstract
Common bile duct cancer is a rare malignant disease with a poor prognosis. Five-year overall survival is 18-48%, and more than half of the patients relapse within five years.
Metastases in the regional lymph nodes and the presence of tumor cells in the margin of the resection are independent factors of a negative prognosis and are associated with a high risk of recurrence.
The clinical significance of other prognostic factors, such as renal invasion, low degree of differentiation, tumor size, pancreatic invasion and the need for resection of adjacent organs, require further study.
About the Authors
A. Yu. Syskova
Pirogov Russian National Research Medical University (RNRMU) of the Health Ministry of Russia; N.N.BLokhin National Medical Research Centre of Oncology of the Health Ministry of Russia
Russian Federation
Russian Federation
PhD student, department of oncology and radiation therapy, faculty of therapy; , graduate student in the department of liver and pancreas tumors
1 Ostrovityanova str., Moscow 1 17997; 23 Kashirskoe sh., 1 15478
I. S. Stilidi
Pirogov Russian National Research Medical University (RNRMU) of the Health Ministry of Russia; N.N.BLokhin National Medical Research Centre of Oncology of the Health Ministry of Russia
Russian Federation
Russian Federation
corr. member of RAS, MD, PhD, DSc, professor, head of the department of oncology and radiotherapy of the medical faculty ; Director
1 Ostrovityanova str., Moscow 1 17997; 23 Kashirskoe sh., 1 15478
A. N. Polyakov
N.N.BLokhin National Medical Research Centre of Oncology of the Health Ministry of Russia
Russian Federation
Russian Federation
MD, PhD, senior researcher, department of liver and pancreas tumors
23 Kashirskoe sh., 1 15478
References
1. Zhou Y, Liu S, Wu L, Wan T. Survival after surgical resection of distal cholangiocarcinoma: A systematic review and meta-analy¬sis of prognostic factors. Asian J Surg. 2017 Apr;40 (2):129-138. DOI: 10.1016/j.asjsur.2015.07.002
2. Ethun CG, Lopez-Aguiar AG, Pawlik TM, Poultsides G, Idrees K, Fields RC, et al. Distal Cholangiocarcinoma and Pancreas Adeno¬carcinoma: Are They Really the Same Disease? A 13-Institution Study from the US Extrahepatic Biliary Malignancy Consortium and the Central Pancreas Consortium. J Am Coll Surg. 2017 Apr;224 (4):406—413. DOI: 10.1016/j.jamcollsurg.2016.12.006
3. Petrova E, Ruckert F, Zach S, Shen Y, Weitz J, Grutzmann R, et al. Survival outcome and prognostic factors after pancreato-duodenectomy for distal bile duct carcinoma: a retrospective multicenter study. Langenbecks Arch Surg. 2017 Aug;402 (5):831- 840. DOI: 10.1007/s00423—017—1590—9.
4. Bergquist A, von Seth E. Epidemiology of cholangiocarcinoma. Best Pract Res Clin Gastroenterol. 2015 Apr;29 (2):221-32. DOI: 10.1016/j.bpg.2015.02.003
5. Каприн А. Д., Старинский В. В., Петрова Г. В. Злокачествен-ные новообразования в России в 2016 году. М.: МНИОИ им. П. А. Герцена — филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2018./Kaprin AD, Starinskii VV, Petrova GV. Malignant neoplasms in Russia in 2016. Moscow: P. Hertsen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Centre of the Ministry of Health of the Russian Federation, 2018. (In Russian).
6. Komaya K, Ebata T, Shirai K, Ohira S, Morofuji N, Akutagawa A, et al. Recurrence after resection with curative intent for distal cholangiocarcinoma. Br J Surg. 2017 Mar;104 (4):426-433. DOI: 10.1002/bjs.10452
7. Andrianello S, Paiella S, Allegrini V, Ramera M, Pulvirenti A, Malleo G, et al. Pancreaticoduodenectomy for distal cholangio-carcinoma: surgical results, prognostic factors, and long-term follow-up. Langenbecks Arch Surg. 2015 Jul;400 (5):623-8. DOI: 10.1007/s00423—015—1320—0.
8. Kim B, Kim K, Chie E, Kwon J, Jang JY, Kim SW, et al. Long-Term Outcome of Distal Cholangiocarcinoma after Pancreaticoduo¬denectomy Followed by Adjuvant Chemoradiotherapy: A 15-Year Experience in a Single Institution. Cancer Res Treat. 2017 Apr;49 (2):473—483. DOI: 10.4143/crt.2016.166
9. Kim N, Lee H, Min S, Lee H. Bile duct segmental resection ver¬sus pancreatoduodenectomy for middle and distal common bile duct cancer. Ann Surg Treat Res. 2018 May;94 (5):240-246. DOI: 10.4174/astr.2018.94.5.240
10. Ecker B, Vining C, Roses R, Maggino L, Lee MK, Drebin JA, et al. Identification of Patients for Adjuvant Therapy After Resection of Carcinoma of the Extrahepatic Bile Ducts: A Propensity Score- Matched Analysis. Ann Surg Oncol. 2017 Dec;24 (13):3926-3933. DOI: 10.1245/s10434—017—6095—9
11. Hester C, Nassour I, Adams-Huet B et al. Improved Survival in Surgically Resected Distal Cholangiocarcinoma Treated with Adju¬vant Therapy: a Propensity Score Matched Analysis. J Gastrointest Surg. 2018 Dec;22 (12):2080-2087. DOI: 10.1007/s11605-018- 3875-x
12. Kim H, Kim C, Hur Y, Koh YS, Kim JC, Kim HJ, Cho CK. The prognostic factors for survival after curative resection of distal cholangiocarcinoma: perineural invasion and lympho- vascular invasion. Surg Today. 2014 Oct;44 (10):1879-86. DOI: 10.1007/s00595—014—0846-z
13. Chung Y, Choi D, Choi S, Heo J, Kim D. Prognostic factors fol¬lowing surgical resection of distal bile duct cancer. J Korean Surg Soc. 2013 Nov;85 (5):212-8. DOI: 10.4174/jkss.2013.85.5.212.
14. Wellner U, Shen Y, Keck T, Jin W, Xu Z. The survival outcome and prognostic factors for distal cholangiocarcinoma following surgi¬cal resection: a meta-analysis for the 5-year survival. Surg Today. 2017 Mar;47 (3):271-279. DOI: 10.1007/s00595-016-1362-0
15. DeOliveira M, Cunningham S, CameronJ, KamangarF, WinterJM, Lillemoe KD, et al. Cholangiocarcinoma. Ann Surg. 2007 May;245 (5):755—62. DOI: 10.1097/01.sla.0000251366.62632.d3
16. Tan X, Xiao K, Liu W, Chang S, Zhang T, Tang H. Prognostic factors of distal cholangiocarcinoma after curative surgery: a series of 84 cases. Hepatogastroenterology. 2013 Nov-Dec;60 (128):1892—5.
17. Murakami Y, Uemura K, Hayashidani Y, Sudo T, Ohge H, Sue- da T. Pancreatoduodenectomy for Distal Cholangiocarcinoma: Prognostic Impact of Lymph Node Metastasis. World J Surg. 2007 Feb;31 (2):337-42; discussion 343-4. DOI: 10.1007/s00268- 006-0224-0
18. Lad N, Kooby D. Distal Cholangiocarcinoma. Surg Oncol Clin N Am. 2014 Apr;23 (2):265-87. DOI: 10.1016/j.soc.2013.11.001.
19. Chua T, Mittal A, Arena J, Sheen A, Gill A, Samra J. Resection margin influences survival after pancreatoduodenectomy for dis¬tal cholangiocarcinoma. Am J Surg. 2017 Jun;213 (6):1072-1076. DOI: 10.1016/j.amjsurg.2016.09.049
20. Park Y, Hwang D, Kim J, Lee J, Song K, Shin S, et al. The Prog¬nostic comparison of the longitudinal margin status in distal bile duct cancer: R0 on first bile duct resection vs. R0 after additional resection. J Hepatobiliary Pancreat Sci. 2019 May;26 (5):169-178. doi: 10.1002/jhbp.619
21. Courtin-Tanguy L, Turrini O, Bergeat D, Truant S, Darnis B, Delpero JR, et al. Multicentre study of the impact of factors that may affect long-term survival following pancreaticoduodenec-tomy for distal cholangiocarcinoma. HPB (Oxford). 2018 May;20 (5):405-410. DOI: 10.1016/j.hpb.2017.10.016
22. Courtin-Tanguy L, Rayar M, Bergeat D, Merdrignac A, Har¬noy Y, Boudjema K, et al. The true prognosis of resected distal cholangiocarcinoma. J Surg Oncol. 2016 Apr;113 (5):575-80. DOI: 10.1002/jso.24165
23. Ma L, Qiu J, Zhang Y, Qiu T, Wang B, Chen W, et al. Prognostic factors for operable biliary tract cancer: serum levels of lactate dehydrogenase, a strong association with survival. Onco Targets Ther. 2018 May 4;11:2533-2543. DOI: 10.2147/OTT.S150502
24. Kato Y, Takahashi S, Gotohda N, Konishi M. Prognostic Im-pact of the Initial Postoperative CA19-9 Level in Patients with Extrahepatic Bile Duct Cancer. J Gastrointest Surg. 2016 Aug;20 (8):1435-43. DOI: 10.1007/s11605-016-3180-5
25. Bolm L, Petrova E, Weitz J, Rückert F, Wittel UA, Makowiec F, et al. Prognostic relevance of preoperative bilirubin-adjusted se¬rum carbohydrate antigen 19-9 in a multicenter subset analysis of 179 patients with distal cholangiocarcinoma. HPB (Oxford). 2019 Apr 5. pii: S1365-182X (19)30486-1. DOI: 10.1016/j. hpb.2019.03.363.
26. Lopez-Aguiar A, Ethun C, Pawlik T, Tran T, Poultsides G, Isom C, et al. Association of Perioperative Transfusion with Recurrence and Survival After Resection of Distal Cholangiocarcinoma: A 10-Institution Study from the US Extrahepatic Biliary Malignancy Consortium. Ann Surg Oncol. 2019 Jun;26 (6):1814-1823. DOI: 10.1245/s10434-019-07306-x
Review
For citations:
Syskova A.Yu., Stilidi I.S., Polyakov A.N. PROGNOSTIC FACTORS FOR RESECTABLE COMMON BILE DUCT CANCER. Research and Practical Medicine Journal. 2019;6(2):69-74. (In Russ.) https://doi.org/10.17709/2409-2231-2019-6-2-7
Views:
950
Email this article 